Humanized Monoclonal Antibody for Prevention of Respiratory Syncytial Virus Infection
- 1 September 1998
- journal article
- editorial
- Published by American Academy of Pediatrics (AAP)
- Vol. 102 (3) , 648-651
- https://doi.org/10.1542/peds.102.3.648
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- Palivizumab, a Humanized Respiratory Syncytial Virus Monoclonal Antibody, Reduces Hospitalization From Respiratory Syncytial Virus Infection in High-risk InfantsPediatrics, 1998
- Safety and Immunogenicity of a Purified F Protein Respiratory Syncytial Virus (PFP‐2) Vaccine in Seropositive Children with Bronchopulmonary DysplasiaThe Journal of Infectious Diseases, 1998
- Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasiaThe Pediatric Infectious Disease Journal, 1998
- Development of a Humanized Monoclonal Antibody (MEDI‐493) with Potent In Vitro and In Vivo Activity against Respiratory Syncytial VirusThe Journal of Infectious Diseases, 1997
- RSV-IGIV Therapy: A Cost/Benefit AnalysisPediatrics, 1997
- Reduction of Respiratory Syncytial Virus Hospitalization Among Premature Infants and Infants With Bronchopulmonary Dysplasia Using Respiratory Syncytial Virus Immune Globulin ProphylaxisPediatrics, 1997
- Respiratory syncytial virus–enriched globulin for the prevention of acute otitis media in high-risk childrenThe Journal of Pediatrics, 1996
- A Trial of RSV Immune Globulin in Infants and Young Children: The FDA's ViewNew England Journal of Medicine, 1994
- Prophylactic Administration of Respiratory Syncytial Virus Immune Globulin to High-Risk Infants and Young ChildrenNew England Journal of Medicine, 1993
- Risk of respiratory syncytial virus infection for infants from low-income families in relationship to age, sex, ethnic group, and maternal antibody levelThe Journal of Pediatrics, 1981